olivLaw · US equity research
iSpecimen Inc. ISPC
Services-Commercial Physical & Biological Research · SIC 8731 · Vertical: Services-Commercial Physical & Biological Research (SIC 8731)
iSpecimen operates an online marketplace that links life science researchers with biospecimen suppliers in hospital and laboratory networks. The company remains unprofitable, with a net loss of 10,487,532 USD in 2025 and an accumulated deficit of 82,350,149 USD, which makes financing and platform efficiency central questions now.
At the close of 04 Nov 2026, iSpecimen Inc. (ISPC) stock was 0.84 USD (+6.71% on the day), with market capitalisation 2.1 m USD, beta 1.35, 52-week range 0.79–26.96 USD. Latest reported quarter (Q2 2026): revenue of 151.9 k USD (−78.7% YoY), net income of -1.4 m USD, diluted EPS -0.98 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 35.8
- weak (30–45)
- Bollinger (20, 2)
- 0.71 – 1.14
- in the lower half of the band · %B 0.32 · band width 46.9%
- SMA 50 / 200
- 1.19 / 4.70
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.12 / -0.13
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −19.7% | −1.1% | −18.6 pp | — |
| 3 months | −56.1% | −0.5% | −55.6 pp | — |
| 6 months | −85.5% | +4.4% | −89.9 pp | — |
| Year to date | −91.9% | +12.3% | −104.2 pp | — |
| 1 year | −96.8% | +13.5% | −110.3 pp | +14.7% |
| 3 years | −99.8% | +76.4% | −176.2 pp | +18.0% |
| 5 years | −100.0% | +63.7% | −163.7 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.7 m | 1.5 m | 1.1 m | 713.1 k | 106.6 k | 51.8 k | 156.0 k | 151.9 k |
| Cost of revenue | 1.6 m | 1.3 m | 609.4 k | 444.2 k | 204.6 k | 551.0 k | 84.4 k | 83.3 k |
| Operating income | -1.7 m | -5.8 m | -1.6 m | -1.8 m | -2.8 m | -2.7 m | -2.5 m | -1.4 m |
| Depreciation & amortisation | 542.8 k ≈ | 548.0 k | 432.7 k | 432.7 k ≈ | 457.7 k ≈ | 407.7 k | 135.9 k | 201.5 k ≈ |
| Interest expense | 7.4 k | 157.5 k | 1.9 k | 0 ≈ | 2 | 1 | — | — |
| Net income | -1.4 m | -6.0 m | -1.7 m | -1.0 m | -2.8 m | -5.0 m | -2.3 m | -1.4 m |
| Diluted EPS | -2.10 | -5.36 ≈ | -28.55 | -16.78 | -0.48 | -0.65 ≈ | -6.66 | -0.98 |
| Operating cash flow | -1.1 m ≈ | -3.6 m | -1.1 m | -192.2 k ≈ | -2.0 m ≈ | -916.9 k | -3.4 m | -689.6 k ≈ |
| Capex | 14.5 k ≈ | 7.9 k | — | — | 0 ≈ | 0 | — | — |
| Share repurchases | 0 ≈ | — | — | — | — | — | — | — |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 8.2 m | 11.1 m | 10.4 m | 9.9 m | 9.3 m | 1.9 m |
| Revenue YoY | unavailable | +36.1% | −6.6% | −4.6% | −6.4% | −79.2% |
| Net income | -4.7 m | -9.0 m | -10.2 m | -11.1 m | -12.5 m | -10.5 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | -4.97 | -2.09 | -1.16 | -24.55 | -17.58 | -2.28 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | -56.8% | -80.5% | -98.5% | -111.8% | -134.5% | -543.7% |
| Free cash flow | -288.8 k | -10.7 m | -6.0 m | -5.8 m | -8.3 m | -4.2 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 6.9 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 3.1 m USD
- Total assets
- 9.5 m USD
- Debt / equity
- unavailable
- Current ratio
- 1.12x
- ROE
- -327.8%
- ROA
- -111.1%
- FCF margin
- -219.9%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 8.2 m | 11.1 m | 10.4 m | 9.9 m | 9.3 m | 1.9 m | SEC (XBRL)· 01 Apr 2026verified |
| Cost of revenue | 3.6 m | 5.2 m | 4.8 m | 4.8 m | 5.1 m | 1.7 m | SEC (XBRL)· 01 Apr 2026verified |
| Gross profit | 4.6 m ≈ | 5.9 m ≈ | 5.6 m ≈ | 5.2 m ≈ | 4.2 m ≈ | 215.7 k ≈ | SEC (XBRL)· 01 Apr 2026derived |
| Research & development | 319.2 k | 879.2 k | 1.5 m | 1.6 m | 1.5 m | — | SEC (XBRL)· 14 Apr 2025verified |
| Operating income | -2.4 m | -5.9 m | -10.2 m | -11.2 m | -12.7 m | -9.0 m | SEC (XBRL)· 01 Apr 2026verified |
| Depreciation & amortisation | — | — | — | 2.1 m | 2.3 m | 1.7 m | SEC (XBRL)· 01 Apr 2026verified |
| EBITDA | — | — | — | -9.1 m ≈ | -10.4 m ≈ | -7.2 m ≈ | SEC (XBRL)· 01 Apr 2026derived |
| Interest expense | 2.1 m | 2.1 m | 239.0 k | 16.0 k | 173.8 k | 1.9 k | SEC (XBRL)· 01 Apr 2026verified |
| Income tax | 0 | 0 | 0 | — | — | — | SEC (XBRL)· 21 Mar 2023verified |
| Net income | -4.7 m | -9.0 m | -10.2 m | -11.1 m | -12.5 m | -10.5 m | SEC (XBRL)· 01 Apr 2026verified |
| Diluted EPS | -4.97 | -2.09 | -1.16 | -24.55 | -17.58 | -2.28 | SEC (XBRL)· 01 Apr 2026verified |
| Weighted average diluted shares | 936.2 k | 4.3 m | 8.8 m | 452.1 k | 710.9 k | 4.6 m | SEC (XBRL)· 01 Apr 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Revenue − Cost of revenue; Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 695.9 k | 27.7 m | 15.3 m | 2.3 m | 1.9 m | 6.9 m | SEC (XBRL)· 01 Apr 2026verified |
| Receivables | 1.5 m | 3.0 m | 1.6 m | 728.4 k | 1.4 m | 48.3 k | SEC (XBRL)· 01 Apr 2026verified |
| Inventories | — | — | — | — | 45.1 k | — | SEC (XBRL)· 01 Apr 2026verified |
| Current assets | 3.5 m | 32.9 m | 19.7 m | 8.2 m | 3.6 m | 7.0 m | SEC (XBRL)· 01 Apr 2026verified |
| Property, plant & equipment, net | 75.6 k | 32.8 k | 225.9 k | 127.8 k | 93.6 k | 25.5 k | SEC (XBRL)· 01 Apr 2026verified |
| Total assets | 6.2 m | 35.7 m | 24.6 m | 15.8 m | 9.4 m | 9.5 m | SEC (XBRL)· 01 Apr 2026verified |
| Accounts payable | 1.8 m | 832.7 k | 2.5 m | 3.9 m | 4.2 m | 5.4 m | SEC (XBRL)· 01 Apr 2026verified |
| Long-term debt | — | 3.4 m | — | — | — | — | SEC (XBRL)· 22 Mar 2022verified |
| Current liabilities | 22.1 m | 2.5 m | 4.3 m | 6.0 m | 5.8 m | 6.2 m | SEC (XBRL)· 01 Apr 2026verified |
| Total liabilities | 22.3 m | 5.9 m | 4.3 m | 6.1 m | 6.0 m | 6.4 m | SEC (XBRL)· 01 Apr 2026verified |
| Equity | -27.3 m † | 29.8 m † | 20.3 m † | 9.7 m † | 3.3 m † | 3.1 m † | SEC (XBRL)· 01 Apr 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -288.4 k | -10.7 m | -5.8 m | -5.8 m | -8.3 m | -4.2 m | SEC (XBRL)· 01 Apr 2026verified |
| Capex | 426 | 2.6 k | 215.5 k | 19.5 k | 31.5 k | 454 | SEC (XBRL)· 01 Apr 2026verified |
| Free cash flow | -288.8 k ≈ | -10.7 m ≈ | -6.0 m ≈ | -5.8 m ≈ | -8.3 m ≈ | -4.2 m ≈ | SEC (XBRL)· 01 Apr 2026derived |
| Investing cash flow | -1.1 m | -1.0 m | -3.2 m | -7.2 m | 2.0 m | -1.0 m | SEC (XBRL)· 01 Apr 2026verified |
| Financing cash flow | 2.0 m | 38.7 m | -3.4 m | 70.9 k | 5.8 m | 10.2 m | SEC (XBRL)· 01 Apr 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 5 of at least 6
- score weight coverage: 33.3% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 2.1 m USD
Key indicators
Coverage and freshness
Score by group
33% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 5 of at least 6; score weight coverage: 33.3% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -2,449.0% | 9 (vs peers) | 19% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | -43.0% | 0 (on a fixed band) | 25% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -4,833.0x | 0 (on a fixed band) | 19% |
| Current ratio · Balance sheet | 0.8x | 2 (on a fixed band) | 13% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -329.9% | 0 (on a fixed band) | 25% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet1/100 · 2/3 factors with a value
- Growth· partial0/100 · 1/2 factors with a value
- Quality· partial9/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
iSpecimen Inc. (ISPC). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 1.9 m USD in 2025; YoY growth -79.2%; net margin -2,449.0%; ROE -968.5%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 5 of at least 6; score weight coverage: 33.3% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
No signal among the computed factors. That is not an absence of risk: factors without data were not assessed, and business risks (margins, inventory, demand) are in the source-based analysis.
What contradicts it
- Net margin: -2,449.0%
- Revenue CAGR 3Y: -43.0%
- Interest coverage: -4,833.0x
- Current ratio: 0.8x
- FCF yield: -329.9%
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Services-Commercial Physical & Biological Research (SIC 8731) · same industry (4-digit SIC) · compared with 11 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| IQVIqvia Holdings Inc. | 43.5 bn | 32.0 | 21.7% | 8.1% | +5.9% | +15% / +23% |
| INCYIncyte Corporation | 25.0 bn | 65.2 | 7.8% | 6.7% | +21.2% | +18% / +126% |
| MEDPMedpace Holdings, Inc. | 18.4 bn | 36.4 | 117.9% | 18.2% | +20.0% | +11% / +143% |
| CRLCharles River Laboratories International, Inc. | 15.6 bn | 385.5 | 1.2% | 1.0% | −0.9% | +83% / +66% |
| ICLRICON plc | 15.6 bn | 70.0 | 2.5% | 2.8% | +0.8% | +10% / −24% |
| ABSIAbsci Corp | 1.8 bn | — | -57.7% | -7,756.4% | −38.2% | +231% / +528% |
| OABIOmniab, Inc. | 755.6 m | — | -16.5% | -108.1% | −29.3% | +186% / +18% |
| NRCNRC Health | 574.5 m | 95.9 | 248.1% | 4.5% | −4.0% | +59% / −35% |
| ONMDOnemednet Corporation | 269.2 m | — | — | -584.2% | +111.4% | −75% / −89% |
| MXCTMaxCyte, Inc. | 143.5 m | — | -20.4% | -114.8% | −14.5% | −21% / −71% |
| BIAFbioAffinity Technologies, Inc. | 23.7 m | — | -1,860.2% | -257.3% | −34.2% | −87% / −100% |
| ISPCiSpecimen Inc. | 2.1 m | — | -968.5% | -2,449.0% | −79.2% | −97% / −100% |
1- and 3-year price returns: for ISPC from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
iSpecimen operates an online marketplace that links life science researchers with biospecimen suppliers in hospital and laboratory networks. The company remains unprofitable, with a net loss of 10,487,532 USD in 2025 and an accumulated deficit of 82,350,149 USD, which makes financing and platform efficiency central questions now 1.
SWOT
Strengths
- The platform combines search, workflow, data and compliance capabilities in one integrated system 1.
- The company has delivered specimens for thousands of projects since inception, showing operating experience 1.
- The just-in-time model avoids the inventory risks that traditional biorepositories carry 1.
Weaknesses
- The company is unprofitable with a significant accumulated deficit, so reliance on external financing remains high 1.
- Revenue is transactional rather than recurring, which makes forecasting difficult 1.
- The company reported a material weakness in internal control over financial reporting related to sales tax 1.
Opportunities
Risks
- Need for additional capitalhigh
The company says it will need additional funding and cannot be certain it will obtain it on acceptable terms 1.
- Going concern doubthigh
The auditors included an explanatory paragraph on the company's ability to continue as a going concern, based on recurring losses and accumulated deficits 1.
- Customer concentrationmedium
A single customer accounted for a significant share of revenue in 2024 and 2025, and revenue varies from year to year 1.
- Material weakness in internal controlmedium
The company identified a weakness linked to sales tax, with remediation under way whose effectiveness is not yet proven 1.
- International expansion riskslow
Operating in several countries exposes the company to political change, different trade rules and currency fluctuations 1.
Investment thesis
What would need to be true (bull case)
- If the platform succeeds in integrating patient data and automating workflows, it could become a more efficient tool for researchers and suppliers.
- Experience delivering specimens across thousands of projects could support expansion into new business lines.
- If research spending recovers, demand for specimens could grow quickly from the current customer base.
What would break the thesis
- The company could remain unprofitable for a long period, and the need for external financing could dilute existing shareholders.
- Transactional revenue and dependence on a few large customers make results difficult to forecast.
- Competition from better-resourced players could limit the platform's growth and margins.
What to watch
- Integration of specimen data into the new SalesStack platformnext 10-K
- Revenue and customer trends after the May 2026 private placementQ3 2026
- Remediation of the internal control weakness on sales taxnext 10-K
- Confirmation of going concern status and the financing plan2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
iSpecimen, founded in 2009 and headquartered in Woburn, Massachusetts, develops the iSpecimen Marketplace, a platform that connects researchers to subjects, specimens and associated data 1. The platform receives de-identified data from electronic medical records and biobank systems, harmonizes it, and lets researchers search for specimens using their study criteria 1. The company handles marketing, sales, contracting and compliance on both sides of the marketplace, and earns revenue from specimen sales, with a share returned to suppliers 1.
Segments
Biospecimen sales
Main revenue comes from procuring specimens from the supplier network and distributing them to researchers on a 'just in time' basis after an order is received 1. The company has derived substantially all revenue from this activity and has not yet charged fees for platform access 1.
Market context
The company describes the biospecimen procurement market as fragmented and inefficient, with samples held in hospitals and laboratories but hard for researchers to access 1. At year-end 2025 its network had data on 19 million patients and 105 million clinical specimen records, though not all data is yet integrated into the new platform 1.
Trends
- Slower research spendingheadwind
The company notes its financial performance depends on research customers' spending, especially discretionary spending, and a recession could reduce demand for specimens 1. Management responded by repricing and reducing headcount, which could support efficiency if demand recovers 1.
- Digitizing specimen procurementtailwind
Moving the platform to a cloud-native architecture across AWS, GCP and Azure could reduce friction in supplier workflows 1. If data migration is completed, matching researcher needs to available supply could become more precise 1.
- Access to capitalmixed
The company raised money through private placements and public offerings in 2025 and 2026, but says it will need additional capital 12. If financing becomes costly, platform development could slow 1.
- Patient data regulationmixed
The company says de-identification and compliance with HIPAA and other rules on specimen use are essential to its model 1. International expansion could bring different legal requirements and added risk 1.
Competitive position
The analysed sources do not explicitly name direct competitors. The company does note that the attractiveness of a fast-moving market could draw rivals with greater resources, and that consolidation in the biospecimen industry could intensify competition 1.
- Biospecimen suppliers and biobanks in the company's network
Hospitals, laboratories and biobanks supply specimens to the platform; the relationship is partnership-based, but they compete indirectly for access to data 1.
- Rival specimen procurement platforms
The company warns that new third-party marketplace technology could make it easier for rivals to build their own platforms 1.
- Consolidated biospecimen industry groups
Consolidation in the industry could increase competitive pressure and the cost of pursuing new opportunities 1.
- Medical data and clinical trial recruitment services
The company intends to enter patient recruitment for clinical trials and data licensing, where it could meet established players 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Intel ISPC 1.32 Released With AVX10.2 & APX Support, Even AMD Zen 6 TooPhoronix · 13 Oct 2026 · EN
The latest news item in our archive is from 13 Oct 2026; the newest SEC filing is from 02 Nov 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Current report02 Nov 2026Shareholder vote
- Current report09 Oct 2026Shareholder vote
- Proxy statement14 Sept 2026
- Current report10 Sept 2026Delisting notice
- Current report04 Sept 2026Material agreement · Financial statements and exhibits
- Current report31 Aug 2026Departure or appointment of officers · Financial statements and exhibits
- Current report14 Aug 2026Material agreement · Financial statements and exhibits
- Quarterly report14 Aug 2026
- Current report11 Aug 2026Material agreement · Termination of a material agreement · Financial statements and exhibits
- Current report07 Aug 2026Material agreement · Regulation FD disclosure · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / iSpecimen Inc. · 01 Apr 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / iSpecimen Inc. · 14 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / iSpecimen Inc. · 06 Aug 2024
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.